CLASSYS (214150) Q2 2026 earnings summary

Executive summary

• Operates in the aesthetic medical device sector, focusing on HIFU, RF, MNRF, and laser technologies, with global sales in over 80 countries and a diversified product portfolio including consumables and home-care devices.

• Completed a significant merger with Ilooda in October 2024, expanding its product and technology base, and acquired several subsidiaries in South America to strengthen direct sales channels.

• Maintains a robust R&D program, investing 7.6% of sales in the latest half-year, and holds over 1,300 registered intellectual property rights globally.

Financial highlights

• H1 2026 consolidated revenue: KRW 192.7 billion, down from KRW 336.8 billion in FY2025 and KRW 242.9 billion in FY2024.

• Operating income for H1 2026: KRW 81.1 billion; net income attributable to owners: KRW 62.0 billion.

• Gross margin for H1 2026: 73.5%; basic EPS: KRW 950 (H1 2026), up from KRW 859 (H1 2025 H1).

• Cash and cash equivalents at June 2026: KRW 78.7 billion, up from KRW 37.5 billion at end-2025.

• Dividend payout for FY2025: KRW 65.2 billion (KRW 1,000 per share), with a payout ratio of 49.4%.

Outlook and guidance

• Expects continued growth in the global aesthetic EBD market, projecting a CAGR of 18% through 2034.

• Strategic focus on expanding direct sales in key overseas markets and leveraging new product launches in MNRF and laser segments.

• Ongoing commitment to shareholder returns, with a policy of sustainable and increasing dividends.